Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18136313 | 0.91 | KCNH2 (0.58) | KCNH2PABPC1KMT2AP2RX7CTSS | |
| SCHEMBL18136314 | 0.88 | KCNH2 (0.55) | KCNH2PABPC1KMT2AP2RX7MEN1 | |
| SCHEMBL1048233 | 0.84 | KCNH2 (0.55) | KCNH2PABPC1P2RX7 | |
| SCHEMBL18136315 | 0.84 | KCNH2 (0.51) | KCNH2PABPC1KMT2ACYP3A4CTSS | |
| SCHEMBL1052038 | 0.84 | KCNH2 (0.62) | KCNH2PABPC1KMT2ACYP3A4MEN1 | |
| SCHEMBL1052236 | 0.83 | KCNH2 (0.54) | KCNH2PABPC1P2RX7 | |
| SCHEMBL17636391 | 0.83 | KCNH2 (0.65) | KCNH2CYP3A4 | |
| SCHEMBL2068503 | 0.83 | KCNH2 (0.57) | KCNH2PABPC1KMT2ACYP3A4P2RX7 | |
| SCHEMBL3769436 | 0.83 | KCNH2 (0.60) | KCNH2PABPC1KMT2ACYP3A4MEN1 | |
| SCHEMBL2068435 | 0.82 | KCNH2 (0.67) | KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | claimed |
| US-9469645-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, SGMS2, FDPS | KCNH2 2202/4885PABPC1 4541/4885KMT2A 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.